

Synthesis and Pharmacological Examination of Some Thiazolidinone Derivatives of Naphtho[2,1-*b*]furan

H. M. VAGDEVI, V. P. VAIDYA*¹, K. P. LATHA, B. PADMASHALI

Department of Chemistry, Sahyadri Science College, Shimoga-577 203, India, ¹Department of Chemistry, Kuvempu University, Jnana Sahyadri, Shankaraghatta-577 451, India.

2-Acetylnaphtho[2,1-*b*]furan (1), obtained from 2-hydroxy-1-naphthaldehyde was converted into 2-bromoacetylnaphtho[2,1-*b*]furan (2), which served as an intermediate for the synthesis of title compounds. The compound (2) was treated with thiourea to get 2-(2-aminothiazol-4-yl)naphtho[2,1-*b*]furan (3), which produced 2-(2-arylideneaminothiazol-4-yl)naphtho[2,1-*b*]furans (4a-i) on reacting with various aromatic aldehydes. Schiff bases (4a-i) yielded 2-[2-(2-aryl-4-thiazolidinone)thiazol-4-yl]naphtho[2,1-*b*]furans (5a-i) on treating with thioglycolic acid. Compound (2) was reacted with different aromatic amines to obtain 2-(*N*-aryl-2-amino)acetylnaphtho[2,1-*b*]furans (6a-k). Similarly reaction with substituted thiourea furnished 2-(2-*N*-arylaminothiazol-4-yl)naphtho[2,1-*b*]furans (7a-k). All the newly synthesized compounds have been characterized by elemental analysis and spectral data, which have been screened for antimicrobial and anthelmintic activities. The selected compounds have been evaluated for antiinflammatory and diuretic activities.

The presence of thiazole moiety in the structure of several naturally occurring molecules with important antibiotic, immunosuppressive and antitumor activities have been known for several years¹⁻⁴. The aminothiazole ring system has found application in drug development for the treatment of HIV-infection, hypertension and inflammation⁵. The several thiazole derivatives have been shown to exhibit excellent bactericidal⁶ fungicidal^{7,8} and anthelmintic⁹ activities. Recently thiazolidinones have been synthesized and screened for possible antimicrobial activities^{10,11}.

Encouraged by these reports and in continuation of our search for pharmacologically potent naphtho[2,1-*b*]furan derivatives,¹²⁻¹⁶ we report in this paper the synthesis of some thiazolidine derivatives of naphtho[2,1-*b*]furan, other related compounds and pharmacological activity of the newly synthesized compounds.

MATERIALS AND METHODS

Melting points were determined in open capillary tubes and are uncorrected. Purity of the compounds was checked by TLC on silica gel G. IR spectra were recorded in KBr on Unicam FTIR (research

spectrophotometer series), NMR spectra on Jeol GSX 270 FT NMR spectrophotometer using TMS as an internal standard (chemical shift in δ , ppm) and mass spectrum on Bruker Apex-II 300 mass spectrophotometer, operating at 70 eV. The pharmacological activities were carried out at National Pharmacy College, Shimoga, (Institutional animals ethics committee, Registration No. 144/1999/CPCSEA/05-07-1999).

2-Acetylnaphtho[2,1-*b*]furan (1):

2-Hydroxy-1-naphthaldehyde (0.1 mol), chloroacetone (0.1 mol) and anhydrous potassium carbonate (10 g) were refluxed in dry acetone (100 ml) for 12 h. Potassium salts were filtered off, the filtrate on removal of solvent and on trituration with ethanol gave the pale yellow crystals of 2-acetylnaphtho[2,1-*b*]furan (1). The sample was recrystallized from absolute ethanol.

2-Bromoacetylnaphtho[2,1-*b*]furan (2):

To a solution of 2-acetylnaphtho[2,1-*b*]furan (1) (0.1 mol) in glacial acetic acid (50 ml) was added a solution of bromine (0.1 mol) in glacial acetic acid (20 ml) with stirring during 1 h at 10-20° and the stirring was continued for 3 h. The reaction mixture was poured into ice-cold water and the solid obtained was filtered out. It was washed with water, dried and the product was recrystallized from ethanol. IR (KBr) cm^{-1} : 1672 (C=O), ¹H NMR (CDCl_3) δ ppm: 3.7 (s, 2H, CH_2) and 6.7-8.5 (m, 7H, Ar-H).

*For correspondence

E-mail: vaidyavijaya@hotmail.com

2-(2-Aminothiazol-4-yl)naphtho[2,1-b]furan (3):

A solution of (2) (0.005 mol) in hot ethanol (50 ml) was treated with thiourea (0.01 mol), to obtain clear solution, which soon deposited some crystals. It was boiled in water (10 ml) containing sodium acetate (2.5 g), which was then filtered, dried and recrystallized from ethanol. IR (KBr) cm^{-1} : 1636 (C=N), 3470, (NH_2), $^1\text{H NMR}(\text{CDCl}_3)$ δ ppm : 3.5 (bs, 2H, NH_2 , D_2O exchangeable), 6.9-9.1 (m, 8H, Ar-H), MS: m/z 266 $[\text{M}]^+$, 250,167,105, 93,83, 77.

2-(2-Arylideneaminothiazol-4-yl)naphtho[2,1-b]furans (4a-i):

Compound (3) (0.01 mol) in ethanol (50 ml) was refluxed with benzaldehyde (0.01 mol) for 6 h in presence of few drops of acetic acid. The solvent was distilled off. The reaction mixture was cooled, poured into ice, filtered, and recrystallized from aqueous dimethyl formamide. The remaining compounds, (4b-i) were synthesized by using appropriate aldehydes similarly. 4f: IR (KBr) cm^{-1} : 1615 (C=N), $^1\text{H NMR}(\text{CDCl}_3)$ δ ppm, 7.2-8.2 (m, 12H, Ar-H), 10.2 (s, 1H, N=CH).

2-[2-(2-Aryl-4-thiazolidinono)thiazol-4-yl]naphtho[2,1-b]furans (5a-i):

A mixture of 2-(2-arylideneaminothiazol-4-yl)naphtho[2,1-b]furan, (4a), (0.01 mol) and mercaptoacetic acid (0.01 mol) in DMF (25 ml) containing pinch of anhydrous zinc chloride was heated under reflux for 5 h. The reaction mixture was cooled and poured onto crushed ice. The solid thus separated was filtered, washed with water and recrystallized from methanol to obtain 5a; IR (KBr) cm^{-1} : 1675 (C=O), $^1\text{H NMR}(\text{CDCl}_3)$ δ ppm, 3.3 (s, 1H, CH), 4.2 (s, 2H, CH_2), 7.3-8.2 (m, 13H, Ar-H). Compounds (5b-i) were prepared similarly from (4b-i) by using mercaptoacetic acid.

2-(N-Aryl-2-amino)acetylnaphtho[2,1-b]furans (6a-k):

An equimolar mixture of appropriate aromatic amines and 2-bromoacetylnaphtho[2,1-b]furan (2) in ethanol (50 ml) was refluxed for 5 h, cooled and poured onto ice cold water. The solid mass thus obtained was filtered and recrystallized from absolute ethanol. 6e: IR (KBr) cm^{-1} : 1669 (C=O), 3260 (NH), $^1\text{H NMR}(\text{CDCl}_3)$ δ ppm, 2.9 (s, 2H, CH_2), 3.9 (s, 3H, OCH_3), 6.8-8.5 (m, 11H, ArH), and 9.2 (bs, 1H, NH, exchangeable with D_2O).

2-[2-Arylaminothiazol-4-yl]naphtho[2,1-b]furans (7a-k):

Arylthiourea (0.01 mol) and 2-bromoacetylnaphtho[2,1-b]furan (2) (0.01 mol) in ethanol (50 ml) were mixed and the mixture

was heated under reflux for 3 h. The reaction mixture was then cooled, poured onto water, and neutralized with aqueous 5% sodium acetate solution. The solid mass thus obtained was collected by filtration, washed with water and recrystallized from aqueous dimethyl formamide. 7a: IR (KBr) cm^{-1} : 1630 (C=N), 3330 (NH). $^1\text{H NMR}$ δ ppm: 7.1-8.4 (m, 14H, ArH). 7h, IR: 1622 (C=N), 3395 (NH_2), $^1\text{H NMR}$: 1.5 (s, 3H, CH_3), 7.4-8.2 (m, 12H, ArH), 9.1 (bs, 1H, NH, exchangeable with D_2O). The physical data of the synthesized compounds is presented in Table 1.

Antimicrobial activity:

The antimicrobial activity was determined by cup-plate method.^{17,18} Pure cultures of the test microorganisms were procured from the cultures maintained at National College of Pharmacy, Shimoga. The *in vitro* antimicrobial activity was carried out against 24 h culture of two bacteria and two fungi. The bacteria used were *Staphylococcus aureus* and *Klebsiella pneumoniae*, while the fungi used were *Aspergillus niger* and *Candida albicans*. The compounds were tested at a concentration of 0.001 mol/ml in dimethyl formamide against both the organisms. Ciprofloxacin (0.001 mol/ml) and ciclopirox olamine (0.001 mol/ml) were used as standards for comparison of antibacterial and antifungal activities, respectively. The zone of inhibition was compared with the standard drug after 24 h of incubation at 37° for antibacterial activity and 72 h at 25° for antifungal activity. The results are reported in Table 2.

Anthelmintic activity:

The earthworms (*Peritima posthuma*, Order-annelida, Class-oligochaeta) were used to evaluate anthelmintic activity¹⁹. The test compounds 0.001 mol/ml in 25 ml suspension of 0.1% Tween-80 solution, 25 ml of 6% dextrose, 25 ml 0.1% Tween-80 solution and 25 ml of piperazine citrate solution (Standard) were poured into separate petridishes as test sample, control, blank, and standard respectively. Three worms were placed in each petridish and the time taken by worm to become motionless was noted as paralysis time and the time taken for complete death of worms was also recorded. The results are reported in Table 2.

Antiinflammatory activity:

Winter's hind paw method²⁰ was used for the evaluation of the antiinflammatory activity of compounds. Wistar rats of either sex weighing 140-200 g were divided into six groups of four animals each. Carrageenan, an irritant, was injected sub-cutaneously into the hind paw of the albino rats at a concentration of 1 mg/ml to produce the edema. Acacia mucilage (2%) was given to one set of animals as control. Another set received the standard drug, ibuprofen

TABLE 1: PHYSICAL CONSTANTS OF THE SYNTHESIZED COMPOUNDS

Compd.	Mol. formula	R	Yield (%)	m.p. (°)	Found % calculated	
					N	
1	C ₁₄ H ₁₀ O ₂	-	66	97	-	-
2	C ₁₄ H ₉ O ₂ Br	-	80	180	-	-
3	C ₁₅ H ₁₀ N ₂ SO	-	55	210	-	-
4a	C ₂₂ H ₁₄ N ₂ SO	C ₆ H ₅	45	230	7.80	7.91
4b	C ₂₂ H ₁₄ N ₂ SO ₂	2-OH C ₆ H ₄	52	188	7.46	7.57
4c	C ₂₃ H ₁₆ N ₂ SO ₂	2-OCH ₃ C ₆ H ₄	48	198	7.10	7.29
4d	C ₂₃ H ₁₆ N ₂ SO ₂	4-OCH ₃ C ₆ H ₄	42	235	7.20	7.29
4e	C ₂₃ H ₁₆ N ₂ SO ₃	4-OH 3- OCH ₃ C ₆ H ₃	62	245	6.50	7.00
4f	C ₂₂ H ₁₃ N ₂ SOCl	4-Cl C ₆ H ₄	45	210	6.95	7.21
4g	C ₂₂ H ₁₃ N ₂ SO ₃	3-NO ₂ C ₆ H ₄	65	265	10.40	10.53
4h	C ₂₄ H ₁₆ N ₂ SO	CH=CH C ₆ H ₅	46	220	7.20	7.37
4i	C ₂₀ H ₁₂ N ₂ SO ₂	Furyl	68	215	7.94	8.14
5a	C ₂₄ H ₁₆ N ₂ SO ₂	C ₆ H ₅	40	240	6.20	6.54
5b	C ₂₄ H ₁₆ N ₂ SO ₃	2-OH C ₆ H ₄	50	220	6.20	6.31
5c	C ₂₅ H ₁₈ N ₂ SO ₃	2-OCH ₃ C ₆ H ₄	48	238	5.88	6.11
5d	C ₂₅ H ₁₈ N ₂ SO ₃	4-OCH ₃ C ₆ H ₄	48	240	5.95	6.11
5e	C ₂₅ H ₁₈ N ₂ SO ₄	4-OH 3-OCH ₃ C ₆ H ₃	42	255	5.79	5.91
5f	C ₂₄ H ₁₅ N ₂ SO ₂ Cl	4-Cl C ₆ H ₄	50	220	5.80	6.05
5g	C ₂₄ H ₁₅ N ₂ SO ₄	3-NO ₂ C ₆ H ₄	70	280	8.40	8.88
5h	C ₂₆ H ₁₈ N ₂ SO ₂	CH=CH C ₆ H ₅	42	245	6.10	6.17
5i	C ₂₂ H ₁₄ N ₂ SO ₃	Furyl	68	265	6.54	6.70
6a	C ₂₀ H ₁₅ NO ₂	C ₆ H ₅	50	210	4.45	4.65
6b	C ₂₁ H ₁₅ NO ₄	4-COOH C ₆ H ₄	60	220	3.95	4.06
6c	C ₂₀ H ₁₄ BrNO ₂	4-Br C ₆ H ₄	50	185	3.18	3.68
6d	C ₂₀ H ₁₅ NO ₃	4-OH C ₆ H ₄	55	190	4.40	4.42
6e	C ₂₁ H ₁₇ NO ₃	4-OCH ₃ C ₆ H ₄	65	180	4.02	4.23
6f	C ₂₁ H ₁₇ NO ₂	2-CH ₃ C ₆ H ₄	40	220	4.25	4.44
6g	C ₂₁ H ₁₇ NO ₂	3-CH ₃ C ₆ H ₄	50	195	4.20	4.44
6h	C ₂₁ H ₁₇ NO ₂	4-CH ₃ C ₆ H ₄	60	180	4.30	4.44
6i	C ₂₀ H ₁₄ N ₂ O ₄	2-NO ₂ C ₆ H ₄	60	225	7.75	8.09
6j	C ₂₀ H ₁₄ N ₂ O ₄	3-NO ₂ C ₆ H ₄	60	180	7.84	8.09
6k	C ₂₀ H ₁₄ N ₂ O ₄	4-NO ₂ C ₆ H ₄	60	220	7.88	8.09
7a	C ₂₁ H ₁₄ N ₂ OS	C ₆ H ₅	50	225	7.95	8.19
7b	C ₂₂ H ₁₄ N ₂ O ₃ S	4-COOH C ₆ H ₄	40	250	7.20	7.25
7c	C ₂₁ H ₁₃ BrN ₂ OS	4-Br C ₆ H ₄	50	260	6.20	6.65
7d	C ₂₁ H ₁₄ N ₂ O ₃ S	4-OH C ₆ H ₄	55	245	7.50	7.82
7e	C ₂₂ H ₁₆ N ₂ O ₃ S	4-OCH ₃ C ₆ H ₄	65	225	7.05	7.53
7f	C ₂₂ H ₁₆ N ₂ OS	2-CH ₃ C ₆ H ₄	50	220	7.40	7.87
7g	C ₂₂ H ₁₆ N ₂ OS	3-CH ₃ C ₆ H ₄	40	240	7.52	7.87
7h	C ₂₂ H ₁₆ N ₂ OS	4-CH ₃ C ₆ H ₄	55	230	7.72	7.87
7i	C ₂₁ H ₁₃ N ₂ O ₃ S	2-NO ₂ C ₆ H ₄	50	250	10.42	10.85
7j	C ₂₁ H ₁₃ N ₂ O ₃ S	3-NO ₂ C ₆ H ₄	50	250	10.42	10.85
7k	C ₂₁ H ₁₃ N ₂ O ₃ S	4-NO ₂ C ₆ H ₄	60	220	10.50	10.85

All the compounds gave satisfactory C and H analysis

(40 mg/kg body weight) and rest of the animals received the test samples (30 mg/kg body weight) orally. The initial volume of the paw was measured plethysmographically within 30 sec of the injection. The relative increase in the paw volume after 3 h of the carrageenan injection was noted. The percentage inhibition of the inflammation was calculated and the results were reported in Table 3.

Diuretic activity:

The activity was evaluated on albino rats by reported

method²¹. The Wistar strain rats weighing 140-200 g of either sex were divided into eight groups of three animals each and placed in metabolic cages, which were provided with a wire mesh at the bottom and a funnel to collect urine. Sieves made up of stainless steel are placed in the funnel to retain feces. The rats were fed with standard diet and water *ad libitum*. Food and water were withdrawn 24 h prior to the experiment. For screening procedure six groups of animals were served test compound and received 30 mg/kg body weight were administered orally,

TABLE 2: ANTIMICROBIAL AND ANTHELMINTIC ACTIVITY OF SYNTHESIZED COMPOUNDS

Compound	Zone of inhibition in mm					
	Antibacterial activity*		Antifungal activity*		Anthelmintic activity (in min)	
	<i>S. aureus</i>	<i>K. pneumoniae</i>	<i>A. niger</i>	<i>C. albicans</i>	Paralysis	Death
4a	08	10	12	14	110	150
4b	-	-	10	12	120	130
4c	-	-	08	10	110	140
4d	12	14	08	14	120	180
4e	-	-	-	-	-	-
4f	10	12	14	16	120	170
4g	16	12	24	22	110	140
4h	12	-	-	12	140	-
4i	-	-	-	06	110	160
5a	14	10	16	18	110	150
5b	-	-	15	-	120	130
5c	10	14	26	28	120	170
5d	-	18	10	-	110	160
5e	15	18	20	24	140	-
5f	18	17	14	20	120	150
5g	-	22	-	-	130	-
5h	-	14	-	15	120	150
5i	18	-	20	24	110	130
6a	26	28	26	24	90	110
6b	-	16	-	-	100	130
6c	10	12	25	24	80	120
6d	20	16	12	-	-	-
6e	-	-	20	22	120	170
6f	14	16	-	22	110	150
6g	-	-	20	18	120	160
6h	24	26	26	26	100	130
6i	15	19	20	24	120	150
6j	12	10	14	16	120	160
6k	-	-	-	-	150	-
7a	24	28	26	24	125	155
7b	-	-	18	16	130	160
7c	26	26	25	24	-	-
7d	20	16	12	10	-	-
7e	13	10	10	12	110	120
7f	06	12	12	-	80	100
7g	15	18	20	18	-	-
7h	24	26	26	26	125	165
7i	15	12	10	14	90	120
7j	10	12	14	16	100	135
7k	-	-	10	16	140	-
Std	24	26	24	22	100	125
Saline	-	-	-	-	Nil	Nil

*Including diameter of the well, control is DMF (0.1% solution in distilled water) and did not show any activity

which was suspended in 0.1% Tween-80. Another set of animals served standard and received 40 mg/kg body weight of frusemide (aqueous solution) orally. The remaining group of animals served as control and received 0.1% Tween-80 solution. Sodium chloride solution (0.9%) at a dose of 5 ml/100 g body weight was given to all the animals by gavage before the experiment. Urine excretion was recorded after 5 h and the values were tabulated in Table 4.

RESULTS AND DISCUSSION

The starting compound 2-acetylnaphtho[2,1-*b*]furan (1)

was synthesized from 2-hydroxy-1-naphthaldehyde by reacting with chloroacetone, anhydrous potassium carbonate in dry acetone. The structure of compound (1) was well established by IR, ¹H NMR, ¹³C NMR and mass spectral studies. The IR spectrum exhibited a peak at 1678 cm⁻¹ which has been attributed to -C=O group. ¹H NMR spectrum showed a singlet at δ 2.6 integrating for 3 protons of -CH₃ group and a multiplet between δ 7.5 and 8.2 integrating for 7 aromatic protons. The decoupled ¹³C NMR spectrum of (1) further confirmed the structure. It revealed peaks at δ 27 due to -CH₃ carbon, δ 111.9 and 112.8 due to carbon atoms of furan ring and a bunch of singlets at, δ 123-131 due to ten

TABLE 3: ANTIINFLAMMATORY ACTIVITY OF SOME SELECTED COMPOUNDS

Compound after 3 h	Paw volume \pm SEM	% protection
Control	1.24 \pm 0.152	–
Ibuprofen	0.30 \pm 0.037	75.8
5a	0.44 \pm 0.060	64.5
5b	0.62 \pm 0.105	50.0
5d	0.46 \pm 0.047	62.9
5f	0.55 \pm 0.085	55.6
5f	0.70 \pm 0.106	43.5

Acute inflammation induced by carrageenan in Wistar rats was used. Number of animals per each group is 4. Standard ibuprofen (40 mg/kg) and test compounds (30 mg/kg) were administered orally. Control group received 2% acacia mucilage. SEM stands for Standard Error Mean

TABLE 4: DIURETIC ACTIVITY OF SOME SELECTED COMPOUNDS

Compound	Volume of urine collected after 5 h	T/S (Lipschitz values)
Std	29	1.00
6a	20	0.69
6h	15	0.52
6k	09	0.31
7a	16	0.55
7h	17	0.58
7k	12	0.41
Control	08	0.27

Animals used were Wistar rats and six animals per group were used. Standard drug used was frusemide. T refers to urine collected for test compound; and S refers to urine collected for standard drug. Control group received 0.1% Tween-80

carbon atoms of naphthalene ring and at δ 188 due to C=O carbon. Mass spectrum of (1), showed molecular ion peak at m/z 210, consistent with the molecular weight with high intensity. Peaks observed at m/z 195, 139, and 43 are in well agreement with expected fragmentation pattern.

The compound (1) was converted into 2-bromoacetylnaphtho[2,1-*b*]furan (2) by bromination in presence of acetic acid at 10-20°, which served as an excellent intermediate for the synthesis of various naphtho[2,1-*b*]furan derivatives. The compound (2) was refluxed with thiourea and the product obtained was identified as 2-(2-aminothiazol-4-yl)naphtho[2,1-*b*]furan (3), on the basis of spectral studies. The compound (3) was made to undergo condensation with various aromatic aldehydes to obtain corresponding Schiff bases, 2-(2-arylideneaminothiazol-4-yl)naphtho[2,1-*b*]furans, (4a-i). On refluxing Schiff bases (4a-i), with thioglycolic acid in dimethyl formamide in the presence of catalytic amount of anhydrous zinc chloride, cyclocondensation took place very smoothly and resulted in the formation of new triheterocyclic compounds, 2-[2-(2-aryl-4-thiazolidinono)thiazol-4-yl]naphtho[2,1-*b*]furans (5a-i).


The compound (2) on reaction with various aromatic amines in ethanol produced 2-(N-aryl-2-amino)acetylnaphtho [2,1-*b*]furans (6a-k). Various substituted thiourea were prepared by the reaction between potassium thiocyanate and appropriate amines, these substituted thiourea on refluxing with compound (2), produced 2-(2-N-arylaminothiazol-4-yl)naphtho[2,1-*b*]furans (7a-k) in good yield (Scheme-1). The structures assigned to the compounds have been established by IR and ¹H NMR spectral studies.

Investigation of antimicrobial activity revealed that the compounds 6a, 6h, 7a, 7c, and 7h exhibited promising activity against all the four organisms, whereas compounds 4g, 5c, and 6c were active against *A. niger* and *C. albicans*. Amongst the compounds tested for anthelmintic activity on *Pheritima posthuma* 6a, 6c, 7f, and 7i were found to be active and it was comparable with the piperazine citrate at the tested dose of 0.001 mol/ml concentration.

Anthelmintic drugs are those which expel the worms. These drugs cause paralysis of worms by penetrating the mucopolysaccharide layer to prevent the movement of worms. This leads to either paralysis or death of the worms. The tested compounds have exhibited considerable anthelmintic activity.

Compound 5a exhibited comparable (64.5%) antiinflammatory percent protection at the dose of 30 mg/kg, while the standard drug ibuprofen showed inhibition of 75.8% after 3 h of drug treatment. Screening results of diuretic activity revealed that the compound 6a exhibited moderate activity. From these results one could conclude that, all the activities are independent of electron withdrawing and electron donating groups in the newly synthesized molecules.

Pain and inflammation is caused due to injury and tissue damage. Carrageenan is an inflammagen and upon administration, it causes inflammation due to the release of histamine, serotonin and kinin, followed by bradykinin, protease, prostaglandin, and lysozyme. Most of the clinically effective non-steroidal antiinflammatory drugs (NSAIDs) are responded to prevent the release of bradykinin, protease, prostaglandin, and lysozyme. Also NSAIDs are effective and can act centrally on CNS or peripherally on ANS. The compounds, which are reported to have antiinflammatory activity are NSAIDs and probably act



Scheme 1: Synthetic scheme for the title compounds

similar to the existing clinically effective agents available now.

Diuretics are agents, which promote the excretion of urine and also increase the rate of excretion of Na^+ and Cl^- . Extra cellular fluid volume is determined by sodium chloride in the body. Diuretics reduce the extra cellular fluid volume by decreasing total body sodium chloride content. Some of the compounds, which are shown to exhibit diuretic activity, are presumed to influence the excretion of sodium and it is well-supported by their antiinflammatory activity, as the inflammation can also be caused due to accumulation of fluid in the joints. However, the mechanisms of action of these compounds are yet to be established.

ACKNOWLEDGMENTS

The authors are grateful to UGC for awarding teacher fellowship to HMV. The authors are also thankful to CDRI, Lucknow, for providing spectral data for the synthesized compounds and to Mr. M. L. Vijay Kumar, National College of Pharmacy, Shimoga, for his help in carrying out pharmacological activities.

REFERENCES

- Mulzer, J., Mantoulider, A. and Ohler, E., *Tetrahedron Lett.*, 1997, 38, 7725.
- Badorc, A., Bordes, M.F., deCointel, P., Savi, P., Lale, A., Petitou, M., Maffrand, J. P. and Herbert, J.M., *J. Med. Chem.*, 1997, 40, 3393.
- Feng, S. and Schreiber, L.S., *J. Med. Chem.*, 1997, 119, 10873.
- Rzasa, M., Shea, H.A. and Romo, D., *J. Amer. Chem. Soc.*, 1998, 120, 591.
- Kearney, P.C., Fernandz, M. and Flygare, J.A., *J. Org. Chem.*, 1988, 63, 196.
- Holla, B.S., Kalluraya, B. and Ambekar, S.Y., *J. Indian Chem. Soc.*, 1987, 64, 494.
- Gawande, N.G. and Shingare, M.S., *Indian J. Chem.*, 1981, 20B, 387.
- Lodhi, R.S., Srivastava, S.D. and Srivastava, S.K., *Indian J. Chem.*, 1998, 37B, 899.
- Kalluraya, B., Rahiman, A.M., David Banji, Isloor, A.M. and Ganesh Rai, *Indian J. Heterocycl. Chem.*, 2000, 9, 217.
- Parmar, J.M., Modha, J.J. and Parikh, A.R., *Indian J. Chem.*, 1998, 38B, 440.
- Galiotta, J.V. and Verkman, A.S., *J. Biol. Chem.*, 2002, 277.
- Vagdevi, H.M. and Vaidya, V.P., *Indian J. Heterocycl. Chem.*, 2001, 10, 253.
- Vagdevi, H.M., Latha, K.P., Vaidya, V.P., Vijaya Kumar, M.L. and Pai K.S.R., *Indian J. Pharm. Sci.*, 2001, 63, 286.
- Mahadevan, K.M., Vaidya, V.P. and Vagdevi, H.M., *Indian J. Chem.*, 2003, 42B, 1931.

- 15 Padmashali, B., Vaidya, V.P. and Vijaya Kumar, M.L., **Indian J. Heterocycl.Chem.**, 2001, 11, 15.
- 16 Latha, K.P., Vaidya, V.P. and Keshavayya, J., **Synth. React. Inorg. Met-Org. Chem.**, 2004, 34, 667.
- 17 Mukhanova, T.I., Lykova, O.A., Alekseeva, L.M. and Granik, V.G., **Chem. Heterocycl. Compd.**, 1998, 34(6), 651.
- 18 "Indian Pharmacopoeia", Controller of Publication Delhi, India II, A-9.1, 1996. 100.
- 19 Giand, K.N., Dar R.N., Chopra, B.N. and Kaul, K.N., **Indian J. Pharm. Sci.**, 1963, 27, 196.
- 20 Hsieh, H.K., Tsao L.T., Wang, J.P. and Lin, C.N., **J. Pharm. Pharmacol.**, 2000, 52(2), 163.
- 21 Lipschitz, W.L., Hadidian, Z. and Kerpesar, A., **J. Pharmacol. Exp. Ther.**, 1943, 79, 97.

Accepted 18 November 2006

Revised 7 March 2006

Received 16 June 2005

Indian J. Pharm. Sci., 2006, 68 (6): 719-725

This PDF is available for free download from
a site hosted by Medknow Publications
(www.medknow.com).